Brief: MannKind Announces IND Clearance From U.S. FDA To Start Phase 3 Study Of Clofazimine Inhalation Suspension For Nontuberculous Mycobacterial Lung Disease
29/04/2024 11:41
April 29 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START
PHASE 3
STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NONTUBERCULOUS
MYCOBACTERIAL (NTM) LUNG DISEASE
* MANNKIND CORP: ANTICIPATES ICON-1, GETTING UNDERWAY BY END
OF 2Q
2024 IN U.S., AND INTERNATIONALLY IN SECOND HALF OF 2024
Source text for Eikon: ID:nGNXNGqjH
Further company coverage: MNKD.O
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children